These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21670885)

  • 1. Cross-disciplinary approaches for measuring parasitic helminth viability and phenotype.
    Peak E; Hoffmann KF
    An Acad Bras Cienc; 2011 Jun; 83(2):649-62. PubMed ID: 21670885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-organism phenotypic screening methods used in early-phase anthelmintic drug discovery.
    Herath HMPD; Taki AC; Rostami A; Jabbar A; Keiser J; Geary TG; Gasser RB
    Biotechnol Adv; 2022; 57():107937. PubMed ID: 35271946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated imaging and other developments in whole-organism anthelmintic screening.
    Paveley RA; Bickle QD
    Parasite Immunol; 2013; 35(9-10):302-13. PubMed ID: 23581722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will technology provide solutions for drug resistance in veterinary helminths?
    von Samson-Himmelstjerna G; Blackhall W
    Vet Parasitol; 2005 Sep; 132(3-4):223-39. PubMed ID: 16118040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthelmintic resistance in human helminths: a review.
    Geerts S; Gryseels B
    Trop Med Int Health; 2001 Nov; 6(11):915-21. PubMed ID: 11703846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance.
    Kerboeuf D; Blackhall W; Kaminsky R; von Samson-Himmelstjerna G
    Int J Antimicrob Agents; 2003 Sep; 22(3):332-46. PubMed ID: 13678840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worms--a "license to kill".
    Kaminsky R; Rufener L; Bouvier J; Lizundia R; Schorderet Weber S; Sager H
    Vet Parasitol; 2013 Aug; 195(3-4):286-91. PubMed ID: 23664156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthelmintic metabolism in parasitic helminths: proteomic insights.
    Brophy PM; MacKintosh N; Morphew RM
    Parasitology; 2012 Aug; 139(9):1205-17. PubMed ID: 22776506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide Approaches to Investigate Anthelmintic Resistance.
    Doyle SR; Cotton JA
    Trends Parasitol; 2019 Apr; 35(4):289-301. PubMed ID: 30733094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthelmintic drug discovery: into the future.
    Geary TG; Sakanari JA; Caffrey CR
    J Parasitol; 2015 Apr; 101(2):125-33. PubMed ID: 25584662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based screening: discovery of the next generation of anthelmintics depends upon more basic research.
    Geary TG; Thompson DP; Klein RD
    Int J Parasitol; 1999 Jan; 29(1):105-12; discussion 113-4. PubMed ID: 10048823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing anthelmintic resistance--parasite fitness, drug use strategy and the potential for reversion towards susceptibility.
    Leathwick DM
    Vet Parasitol; 2013 Nov; 198(1-2):145-53. PubMed ID: 24074608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current drug targets for helminthic diseases.
    Rana AK; Misra-Bhattacharya S
    Parasitol Res; 2013 May; 112(5):1819-31. PubMed ID: 23529336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foreword: towards markers for anthelmintic resistance in helminths of importance in animal and human health.
    Prichard RK; von Samson-Himmelstjerna G; Blackhall WJ; Geary TG
    Parasitology; 2007; 134(Pt 8):1073-6. PubMed ID: 17608966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of anthelmintic resistance.
    Sangster N
    Parasitology; 1996; 113 Suppl():S201-16. PubMed ID: 9051936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics.
    Nixon SA; Welz C; Woods DJ; Costa-Junior L; Zamanian M; Martin RJ
    Int J Parasitol Drugs Drug Resist; 2020 Dec; 14():8-16. PubMed ID: 32814269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming drug resistance for macro parasites.
    Srivastava M; Misra-Bhattacharya S
    Future Microbiol; 2015; 10(11):1783-9. PubMed ID: 26517758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present-day anthelmintics and perspectives on future new targets.
    Taman A; Azab M
    Parasitol Res; 2014 Jul; 113(7):2425-33. PubMed ID: 24894082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-content approaches to anthelmintic drug screening.
    Zamanian M; Chan JD
    Trends Parasitol; 2021 Sep; 37(9):780-789. PubMed ID: 34092518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of the 'Open Scaffolds' collection from Compounds Australia identifies a new chemical entity with anthelmintic activities against different developmental stages of the barber's pole worm and other parasitic nematodes.
    Preston S; Jiao Y; Baell JB; Keiser J; Crawford S; Koehler AV; Wang T; Simpson MM; Kaplan RM; Cowley KJ; Simpson KJ; Hofmann A; Jabbar A; Gasser RB
    Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):286-294. PubMed ID: 28732272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.